SphK1 inhibitor by itself overcomes MDR-associated chemoresistance in AML and CML cell lines and patient samples and gemcitabine-resistant pancreatic cancer cells [115, 116, 178]. Here, SPHK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.